Trial Profile
A retrospective, single center efficacy and safety study of Carfilzomib-based combination regimens as frontline therapies for ultiple Myeloma and WaldenströM's Macroglobulinemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jul 2020
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology